Eye Disease Archives

Best in Biotech 30 Dec 2024

Six biotech companies leading the way in India

Discover six of the top biotech companies in India, which is currently brimming with biotechs and a young, skilled workforce.

December 30, 2024 - 8 minutesmins - By Willow Shah-Neville

In Depth 25 Dec 2024

When biotech makes Christmas miracles a reality

Explore how biotech breakthroughs in 2024 have changed lives, bringing real Christmas miracles to patients and offering hope for the future.

December 25, 2024 - 8 minutesmins - By Jules Adam

Podcast 26 Jul 2024

The first mass-market cell therapy?

Listen to our conversation with CEO Greg Kunst about how Aurion’s treatment could be the first mass-market cell therapy available

July 26, 2024

Podcast 17 May 2024

Isarna Therapeutics revolutionizes ophthalmology with antisense oligonucleotides

German-headquartered Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology – transforming growth factor beta (TGF-B) signaling. Precise modulation of TGF-B pathways using antisense therapy may result in safer and more effective treatment options for a broad range of indications. Isarna Therapeutics’s lead compound, ISTH0036, is in […]

May 17, 2024

Geographic atrophy treatment: Apellis' Syfovre vs. Astellas' Izervay.

In Depth 22 Nov 2023

Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment

Until the approval of Apellis’ Syfovre earlier this year, there was no treatment for geographic atrophy. Shortly after, Astellas’ Izervay was also approved for the eye condition. Now, as the only two companies with approved geographic atrophy treatments, there appears to be an ongoing rivalry between them to see who can come out on top […]

November 22, 2023 - 8 minutesmins - By Willow Shah-Neville

News and Trends 19 Jun 2023

Allgenesis says dry eye patients’ trial data ‘encouraging’

Allgenesis Biotherapeutics Inc., a clinical-stage specialty pharmaceutical company focused on developing novel ophthalmic drugs, has announced topline data from its phase 1b clinical trial for AG-80308, a first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop for the treatment of dry eye disease (DED). AG-80308 was considered safe at all doses […]

June 19, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 12 Jun 2023

Beacon Therapeutics launches with $120M to develop gene therapies for retinal diseases

Beacon Therapeutics Holdings Limited has been launched to develop gene therapies to treat a range of rare and prevalent retinal diseases that result in blindness. Syncona Limited, with additional investors including Oxford Science Enterprises, has provided £96 million ($120 million) to fund the acquisition of AGTC and provide capital to take Beacon Therapeutics’ development candidates […]

June 12, 2023 - 4 minutesmins - By Jim Cornall

Best in Biotech 1 Jun 2023

Five ophthalmology biotech companies to look out for

There are hundreds of different eye diseases, with some of the most common major eye diseases including age-related macular degeneration (AMD) – an age-related eye disease that can blur central vision – glaucoma – a condition where the optic nerve becomes damaged – and diabetic retinopathy (DR) – a complication of diabetes in which high […]

June 1, 2023 - 6 minutesmins - By Willow Shah-Neville

News and Trends 10 May 2023

Cell rejuvenation for age-related diseases

By Sharon Rosenzweig-Lipson, CSO, Life Biosciences Cellular rejuvenation is quickly becoming a hot topic in the development of novel therapeutic modalities for a range of diseases. The leading approaches to cellular rejuvenation currently in development utilize epigenetic reprogramming to achieve this goal. Epigenetics is the study of how positive and negative lifestyle factors (exercise, smoking, […]

May 10, 2023 - 3 minutesmins - By External Contributor

News and Trends 2 May 2023

Astellas eyes ophthalmology field with $5.9B Iveric Bio takeover

Astellas Pharma Inc., through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio, Inc., for $40 per share in cash for a total equity value of approximately U.S. $5.9 billion. Iveric Bio will become an indirectly wholly-owned subsidiary of Astellas. […]

May 2, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 24 Apr 2023

Life Biosciences gene therapy data shows visual function restored in primates

Life Biosciences (Life Bio) has announced preclinical data in nonhuman primates (NHP) for its novel gene therapy candidate, which uses a partial epigenetic reprogramming approach to restore visual function. The approach has been shown to reverse aging, improve vision, and extend lifespan in mice, but whether epigenetic reprogramming would work in primates was not known. […]

April 24, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 21 Apr 2023

RetinAI and Boehringer Ingelheim to use AI to develop treatment for geographic atrophy

RetinAI Medical AG, which creates clinical and imaging data management software and advanced analytics using artificial intelligence (AI) for ophthalmology, is partnering with Boehringer Ingelheim. The companies aim to improve patient outcomes in geographic atrophy (GA) by combining RetinAI’s Discovery platform and AI tools with Boehringer Ingelheim’s research in retinal diseases. GA is a progressive, […]

April 21, 2023 - 2 minutesmins - By Jim Cornall

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Eye Disease

Six biotech companies leading the way in India

When biotech makes Christmas miracles a reality

The first mass-market cell therapy?

Isarna Therapeutics revolutionizes ophthalmology with antisense oligonucleotides

Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment

Allgenesis says dry eye patients’ trial data ‘encouraging’

Beacon Therapeutics launches with $120M to develop gene therapies for retinal diseases

Five ophthalmology biotech companies to look out for

Cell rejuvenation for age-related diseases

Astellas eyes ophthalmology field with $5.9B Iveric Bio takeover

Life Biosciences gene therapy data shows visual function restored in primates

RetinAI and Boehringer Ingelheim to use AI to develop treatment for geographic atrophy

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!